Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances

Figure 4 Efficacy of key active components of Fuling Zexie decoction/Fuling Zexie decoction without Poria against hepatic steatosis. A: Cell oil red O staining (200 ×); B: Cell oil red O staining analysis; C: Cell total cholesterol; D: Cell triglyceride; E: Cell alanine transaminase; F: Cell aspartate transaminase; G: Cell phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; H: Cell aldo-keto reductase family 1 member B10; I: Liver phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; J: Liver phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta; K: Liver aldo-keto reductase family 1 member B1; L: Liver aldo-keto reductase family 1 member B10. ^aP < 0.05 vs the model group, ^bP < 0.01 vs the model group, ^cP < 0.001 vs the model group, ^dP < 0.0001 vs the model group. NC: Normal control; LFZDC: Low-dose key active compound ensemble of Fuling Zexie decoction; HFZD: High-dose Fuling Zexie decoction; LPRC: Low-dose key active compound ensemble of Poria in Fuling Zexie decoction; MOD: Model; LZD: Low-dose Fuling Zexie decoction without Poria; HZD: High-dose Fuling Zexie decoction without Poria; HPR: The key active compound ensemble of Poria in Fuling Zexie decoction; FC: Fenofibrate capsules; LWOC: Low-dose key active compound ensemble of Fuling Zexie decoction without Poria compounds; HWOC: High-dose key active compound ensemble of Fuling Zexie decoction without Poria compounds; LFZD: Low-dose Fuling Zexie decoction; HPRC: High-dose key active compound ensemble of Poria in Fuling Zexie decoction; LFFZD: Low-dose Fuling Zexie decoction supplemented with Poria dregs; HFFZD: High-dose Fuling Zexie decoction supplemented with Poria dregs.